Incyte
NEWS
MorphoSys AG and Incyte Corporation have inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
Company shares dropped almost 10% at the news.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.
Last week was busy for clinical trial news. Here’s a look.
The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
JOBS
IN THE PRESS